Cinnagen İlaç, biyoteknoloji devriminin yaşandığı bugünlerde ülkemizde 3-4 fabrika daha kurmayı hedefliyor. Şirket CEO’su Ferhat Farşi ‘’bu tesisler sayesinde üretilecek ürünlerin hastalara ulaştırılmasıyla birlikte 1,8 milyar dolarlık Türkiye pazarının yaklaşık 500 milyon dolarlık kısmı yerli üretim olacak’’ dedi. Ülkemizde ilk defa monoklonal antikor (mAb) ve yetim ilaçların üretimini yapan firma, 2 yıl sonra tüm Avrupa ülkelerine ihracatın başlayacağı müjdesini de verdi.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
